Eli Lilly's acquisition of Verve brings a boost to the industry, and the gene editing sector sees an increase.

According to the Wise Finance APP, the stock price of a biotechnology company focused on gene therapy has risen. The reason is that Eli Lilly (LLY.US) has agreed to acquire the gene editing startup Verve Therapeutics (VERV.US) in Boston for a total price not exceeding 1.3 billion US dollars, This deal has brought a positive impetus to the struggling industry.